['hypercholesterolemia']
['cat-2054', 'placebo', 'cat-2054-c', 'atorvastatin']

        Inclusion Criteria:

          -  Provision of written informed consent before any study-specific procedure

          -  Good health as determined by medical history, physical examination, vital sign
             measurements, ECG, and clinical laboratory measurements

          -  Satisfies one of the following:

               1. Females not of childbearing potential: non-pregnant and non-lactating surgically
                  sterile or postmenopausal 2 years or less with a follicle-stimulating hormone
                  assessment greater than or equal to 40 IU/L

               2. Males: surgically sterile, abstinent, or subject or partner is utilizing an
                  acceptable contraceptive method during and 3 months after the last study dose

          -  For Part B only, measured at Screening: Fasting LDL-C ≥100 mg/dL; or (Cohort B6 only)
             fasting LDL-C ≥130 mg/dL

          -  Body mass index (BMI) between 18 and 30 kg/m², inclusive, for Part A and between 18
             and 40 kg/m², inclusive, for Part B, and body weight >50 kg at Screening

        Exclusion Criteria:

          -  Use of prescription drugs or non-prescription drugs including herbals, and dietary
             supplements (including multivitamins and any product containing niacin or omega-3
             fatty acids above the Recommended Daily Allowance) within 2 weeks before dosing.
             Additionally for Part B only, use of any lipid-regulating prescription drug,
             non-prescription drug, herbal, or dietary supplement within 6 weeks before dosing

          -  Clinically significant disease that requires a physician's care and/or would interfere
             with study evaluations

          -  Clinically significant electrocardiogram (ECG) abnormalities or laboratory results as
             assessed by the investigator, such as QTcF >450

          -  Use of any investigational drug or participation in any investigational study within
             30 days prior to screening or 5 half-lives of the study agent, whichever is longer
      